Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the
past 30 years, disease-related morbidity and mortality have improved in high-income …

Sickle cell disease (SCD; ORPHA232; OMIM# 603903) is a chronic and invalidating
disorder distributed worldwide, with high morbidity and mortality. Given the disease …

Sickle cell anemia disease has been a great challenge to the world in the present situation.
It occurs only due to the polymerization of sickle hemoglobin (HbS) having Pro–Val–Glu …

The ability to respond rapidly to changes in oxygen tension is critical for many forms of life.
Challenges to oxygen homeostasis, specifically in the contexts of evolutionary biology and …

Voxelotor, a sickle hemoglobin polymerization inhibitor, was approved by the US Food and
Drug Administration to treat sickle cell disease (SCD) in November 2019. This article …

Introduction: Sickle cell disease (SCD) is caused by a mutation in the HBB gene which is key
for making a component of hemoglobin. The mutation leads to the formation of an abnormal …

A 35-y-old African-American male presented to the emergency department at Vanderbilt
University Medical Center for treatment of sickle cell pain crisis. An emergent red blood cell …

Sickle cell disease (SCD) is one of the most common genetic disorders in the world
predominantly affecting economically disadvantaged populations. There is a notable …

Introduction: Acute pain from episodic vaso-occlusion (VOC) spans the lifespan of almost
everyone with sickle cell disease (SCD), while additional chronic pain develops in …

Sickle cell disease (SCD) is a heterogeneous group of inherited disorders characterized by
the production of sickle hemoglobin which is less soluble than an adult or fetal hemoglobin …